| 崙棫堛栻昳怘昳塹惗尋媶強 |
National Institute of Health Sciences |
| 惗暔栻昳晹 |
Division of Biological Chemistry and Biologicals |
|
丂丂丂 |
亂rINN亃briakinumab (List 63, 2010, Vol.24, No.1, p47)
亂pINN亃briakinumab (List 101, 2009, Vol.23, No.2, p136)
亂夝愢乮榓栿乯亃
IgG1兩, 峈僸僩僀儞僞乕儘僀僉儞12兝僒僽儐僯僢僩 (IL12B, IL-12B, IL12 p40, NKSF2, CMLF p40),僸僩儌僲僋儘乕僫儖峈懱;
柶塽挷惍嵻丏
H嵔 (兞1嵔丆1-455)丗[Homo sapiens VH (IGHV3-30*02 (99.00%) -(IGHD)-IGHJ3*01)
[8.8.8] (1-115) -IGHG1*03 R120>K(116-445)]丏
L嵔(兩嵔丆1'-217')丗[Homo sapiens V-LAMBDA (IGLV1-44*01 (88.20%) -IGLJ2*01 G120>T)
[8.3.12] (1'-111') -IGLC2*01 (112'-217')]丏
僕僗儖僼傿僪寢崌偺埵抲丗218-216', 224-224''丆227-227''
摐嵔晅壛埵抲丗295, 295''
亂暘巕幃亃C6376H9874O1992S44
亂CAS斣崋亃151638-93-6
亂JAN亃枹廂嵹
|
|
| Copyright (C) 丂丂丂Division of Biological Chemistry and Biologicals丂丂丂All
rights reserved. |
|
|